JFS Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

JFS Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04K	Buy	33 +30	+1,000%	+$885	﹤0.01%	1799
2026 Q1	$75	Hold	3	–	–	﹤0.01%	1852
2025 Q4	$71	Hold	3	–	–	﹤0.01%	1894
2025 Q3	$60	Hold	3	–	–	﹤0.01%	1861
2025 Q2	$66	Hold	3	–	–	﹤0.01%	1824
2025 Q1	$73	Hold	3	–	–	﹤0.01%	1886
2024 Q4	$63	Hold	3	–	–	﹤0.01%	1904
2024 Q3	$60	Hold	3	–	–	﹤0.01%	1923
2024 Q2	$47	Hold	3	–	–	﹤0.01%	1959
2024 Q1	$48	Sell	3 -2	-40%	-$30	﹤0.01%	1979
2023 Q4	$85	Buy	5 +1	+25%	+$14	﹤0.01%	1961
2023 Q3	$47	Sell	4 -1	-20%	-$13	﹤0.01%	1933
2023 Q2	$68	Buy	5 +4	+400%	+$58	﹤0.01%	1942
2023 Q1	$17	Buy	+1	New	+$16	﹤0.01%	1945

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

JFS Wealth Advisors's CPRX Position: Q2 2026 in Review

JFS Wealth Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 1,000% in Q2 2026, buying an estimated $885 and bringing the position to 33 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #1799.

JFS Wealth Advisors first reported a position in CPRX in Q1 2023 and has held it in 14 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

JFS Wealth Advisors held 33 shares of Catalyst Pharmaceutical worth $1.04K as of Q2 2026.
JFS Wealth Advisors bought 30 Catalyst Pharmaceutical shares in Q2 2026, an estimated $885.
Catalyst Pharmaceutical made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1799 holding.
JFS Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 14 quarters since.
36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.